Variables | Â | N | 6Â M cumulative incidence of G2RP (%) | p value | 6Â M cumulative incidence of discontinuation of Durvalumab due to G2RP (%) | p value | Â |
---|---|---|---|---|---|---|---|
Gender | Male | 37 | 48.7 | 0.038 | 21.6 | 0.03 | Â |
 | Female | 19 | 18.6 |  | 0.0 |  |  |
Pulmonary Fibrosis Score | ≥ 2 | 10 | 90.0 |  < 0.001 | 60.0 |  < 0.001 |  |
 | 0–1 | 46 | 28.3 |  | 4.3 |  |  |
Smoking history | Present | 45 | 46.5 | 0.031 | 17.8 | 0.14 | Â |
 | Never | 11 | 9.0 |  | 0.0 |  |  |
Lung V40 | ≥ 10% | 30 | 57.3 | 0.011 | 20.0 | 0.21 |  |
 |  < 10% | 26 | 16.7 |  | 7.7 |  |  |
Initial PTV | ≥ 398 ml | 24 | 58.3 | 0.024 | 25.0 | 0.048 |  |
 | < 398 ml | 32 | 23.8 |  | 6.3 |  |  |
Multivariate analysis | |||||||
---|---|---|---|---|---|---|---|
Variables | Â | HR | 95% CI | p value | HR | 95% CI | p value |
Pulmonary Fibrosis Score | ≥ 2 | 7.83 | 3.38–18.13 |  < 0.001 | 5.89 | 1.53–22.68 |  < 0.001 |
Lung V40 | ≥ 10% | 3.17 | 1.09–9.19 | 0.034 |  |  |  |
Initial PTV |  |  |  |  | 2.62 | 0.71–9.71 | 0.15 |